Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 113 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Focal Seizure Clear all
Completed Phase 3 Interventional Results available

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699582
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Jul 22, 2026, 3:55 PM EDT
Recruiting Phase 3 Interventional

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

NCT05135091
View directory record Official record
Conditions
Mesial Temporal Lobe Epilepsy
Interventions
NRTX-1001, Sham Comparator
Biological · Procedure
Lead sponsor
Neurona Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2043
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 22, 2026, 3:55 PM EDT
Active, not recruiting Not applicable Interventional

A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy

NCT03417297
View directory record Official record
Conditions
Partial Seizures With Secondary Generalization, Focal Epilepsy With Secondary Generalization
Interventions
High Intensity Focused Ultrasound
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jul 22, 2026, 3:55 PM EDT
Completed Phase 3 Interventional Results available

A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

NCT01463306
View directory record Official record
Conditions
Epilepsy, Partial Seizures, Epilepsy, Primary Generalized Tonic-Clonic Seizures
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Month to 66 Years
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
21
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jul 22, 2026, 3:55 PM EDT
Completed Phase 3 Interventional

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures

NCT00141388
View directory record Official record
Conditions
Seizure Disorder, Partial
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2009 · Synced Jul 22, 2026, 3:55 PM EDT
Completed No phase listed Observational Results available

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

NCT02392078
View directory record Official record
Conditions
Metastatic Brain Tumor, Primary Brain Tumor, Epileptic/Seizure Foci, Movement Disorders
Interventions
NeuroBlate System
Device
Lead sponsor
Monteris Medical
Industry
Eligibility
Not listed
Enrollment
1,153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jul 22, 2026, 3:55 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures

NCT00772603
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Placebo, 2400mg SPN-804, 1200mg SPN-804
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
23
States / cities
Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Jul 22, 2026, 3:55 PM EDT
Terminated Phase 4 Interventional Results available

Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients

NCT01266291
View directory record Official record
Conditions
Complex Partial Seizures
Interventions
vigabatrin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Jul 22, 2026, 3:55 PM EDT
Completed Phase 3 Interventional

Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy

NCT00056576
View directory record Official record
Conditions
Epilepsy, Complex Partial
Interventions
Zonisamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
16 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2011 · Synced Jul 22, 2026, 3:55 PM EDT
Active, not recruiting Phase 4 Interventional

Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

NCT06453213
View directory record Official record
Conditions
Focal Onset Seizure
Interventions
Cenobamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 3:55 PM EDT
Terminated Phase 4 Interventional Results available

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

NCT04650204
View directory record Official record
Conditions
Intractable Epilepsy, Malignant Glioma, Seizure Disorder, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions
Anticonvulsant Agent, Perampanel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 22, 2026, 3:55 PM EDT
Recruiting Phase 3 Interventional

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

NCT07563881
View directory record Official record
Conditions
Focal Seizure, Epilepsy, Focal Epilepsy
Interventions
RAP-219, Placebo
Drug · Other
Lead sponsor
Rapport Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Palmdale, California • Fort Wayne, Indiana • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 22, 2026, 3:55 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

NCT00524030
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
pregabalin 600 mg/day, pregabalin 150 mg/day
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
63
States / cities
Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jul 22, 2026, 3:55 PM EDT
Recruiting Phase 3 Interventional

Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

NCT07505004
View directory record Official record
Conditions
Focal Epilepsy
Interventions
40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks, Placebo
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Miami, Florida • Miami Lakes, Florida • Naples, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 3:55 PM EDT
Completed Phase 3 Interventional Results available

Once-A-Day Pregabalin For Partial Seizures

NCT01262677
View directory record Official record
Conditions
Partial Seizures, Epilepsies, Partial
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
26
States / cities
Northport, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Jul 22, 2026, 3:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Novel Helmet Design in Patients With Seizures

NCT03443388
View directory record Official record
Conditions
Drug Resistant Epilepsy, Drop Seizures, Generalized Tonic Clonic Seizure, Complex Partial Seizure, Fall Due to Seizure
Interventions
Hövding inflatable helmet
Device
Lead sponsor
Michael A. Gelfand, MD, PhD
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Jul 22, 2026, 3:55 PM EDT
Completed Phase 3 Interventional

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

NCT00141336
View directory record Official record
Conditions
Seizure Disorder, Partial
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
97
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 71 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2006 · Synced Jul 22, 2026, 3:55 PM EDT
Enrolling by invitation Phase 3 Interventional

An Open-label Study of XEN1101 in Epilepsy

NCT05718817
View directory record Official record
Conditions
Focal Epilepsy, Tonic-Clonic Seizures
Interventions
XEN1101
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
54
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 3:55 PM EDT
Recruiting Phase 2 Interventional

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

NCT07130786
View directory record Official record
Conditions
Seizures, Primary Motor Cortex, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Adult, Brain Metastases From Extra-cranial Solid Tumors
Interventions
Levetiracetam (Keppra)
Drug
Lead sponsor
Ayal A. Aizer, MD
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 22, 2026, 3:55 PM EDT
Withdrawn Phase 2 Interventional

ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

NCT05481905
View directory record Official record
Conditions
Focal Epilepsy
Interventions
ENX-101
Drug
Lead sponsor
Engrail Therapeutics INC
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Downey, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Jul 22, 2026, 3:55 PM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

NCT06377930
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
RAP-219
Drug
Lead sponsor
Rapport Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
New Haven, Connecticut • Boise, Idaho • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 3:55 PM EDT
Terminated Phase 2 Interventional Results available

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04686786
View directory record Official record
Conditions
Seizures
Interventions
CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Little Rock, Arkansas • New Haven, Connecticut • Gulf Breeze, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 22, 2026, 3:55 PM EDT
Terminated Phase 4 Interventional

Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus

NCT05684978
View directory record Official record
Conditions
Refractory Status Epilepticus
Interventions
Perampanel
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 22, 2026, 3:55 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Focal Electrically-Administered Seizure Therapy (FEAST) Studies at Two Enrolling Sites to Further Test and Refine the Treatment

NCT02535572
View directory record Official record
Conditions
Depression
Interventions
FEAST, RUL UB
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 90 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Augusta, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Jul 22, 2026, 3:55 PM EDT